Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2007

Lilly Taps Aveo to Ascertain Response to Its Oncology Drug Candidate

  • Eli Lilly will use Aveo Pharmaceuticals’ technology to more effectively guide the clinical development of one of its cancer compounds.

    Under the collaboration, Lilly will use the Human Response Platform as part of a pilot project. Lilly hopes to identify genetic profiles that correlate with drug response.

    “This latest collaboration with a global pharmaceutical company indicates the opportunity that our platform provides our select partners and AVEO to increase the efficiency and probability of success of drug development in oncology,” points out Tuan Ha-Ngoc, president and CEO of Aveo. “Ultimately, we believe this will enable us to bring the right drugs to the right patients.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »